GPR139

G-protein coupled receptor 139 (GPC139) is a protein that in humans is encoded by the GPR139 gene.[5][6] Recent research ('21) has shown that mice with loss of GCP139 experience schizophrenia-like symptomatology that is rescued with the dopamine receptor antagonist haloperidol and the μ-opioid receptor antagonist naltrexone;[7] as well, the recently developed, potent, and GPR139 receptor selective agonist TAK-041 (aka NBI-1065846)[8] is currently undergoing trials to gauge the efficacy for treating psychiatric conditions such as major depressive disorder and the negative symptoms of schizophrenia.

GPR139
Identifiers
AliasesGPR139, GPRg1, PGR3, G protein-coupled receptor 139
External IDsOMIM: 618448 MGI: 2685341 HomoloGene: 45860 GeneCards: GPR139
Orthologs
SpeciesHumanMouse
Entrez

124274

209776

Ensembl

ENSG00000180269

ENSMUSG00000066197

UniProt

Q6DWJ6

Q80UC8

RefSeq (mRNA)

NM_001002911
NM_001318483

NM_001024138

RefSeq (protein)

NP_001002911
NP_001305412

NP_001019309

Location (UCSC)Chr 16: 20.03 – 20.07 MbChr 7: 118.74 – 118.78 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

References

  1. GRCh38: Ensembl release 89: ENSG00000180269 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000066197 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, et al. (April 2003). "The G protein-coupled receptor repertoires of human and mouse". Proceedings of the National Academy of Sciences of the United States of America. 100 (8): 4903–4908. Bibcode:2003PNAS..100.4903V. doi:10.1073/pnas.0230374100. PMC 153653. PMID 12679517.
  6. "Entrez Gene: GPR139 G protein-coupled receptor 139".
  7. Dao M, Stoveken HM, Cao Y, Martemyanov KA (March 2022). "The role of orphan receptor GPR139 in neuropsychiatric behavior". Neuropsychopharmacology. 47 (4): 902–913. doi:10.1038/s41386-021-00962-2. PMC 8882194. PMID 33479510. S2CID 231668867.
  8. Reichard HA, Schiffer HH, Monenschein H, Atienza JM, Corbett G, Skaggs AW, et al. (August 2021). "Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia". Journal of Medicinal Chemistry. 64 (15): 11527–11542. doi:10.1021/acs.jmedchem.1c00820. PMID 34260228. S2CID 235908256.

Further reading

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.